Albumin-Bound Paclitaxel(ABX) intravenous drip

Phase 3Small molecule

TThe Third Affiliated hospital of Zhejiang Chinese Medical University

Albumin-Bound Paclitaxel(ABX) intravenous drip is one of 36 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

GliomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

15 2

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 3

Bicnu

MMelissa K Accordino

Phase 3

7 4

Vepesid

AAvyxa

Phase 3

4 5

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 6

Velban

EEastern Cooperative Oncology Group

Phase 3

1 7

Ifex

BBaxter Healthcare Corporation

Phase 3

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 9

Modeyso

CChimerix

Phase 3

3 10

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Glioma

NCT06330337

Clinical

Trials by Indication[1]

Glioma1 trial

Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma

Recruiting·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·Phase 3·NCT06330337·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Albumin-Bound Paclitaxel(ABX) intravenous drip. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albumin-Bound Paclitaxel(ABX) intravenous drip compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albumin-Bound Paclitaxel(ABX) intravenous drip. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Third Affiliated hospital of Zhejiang Chinese Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Third Affiliated hospital of Zhejiang Chinese Medical University

Albumin-Bound Paclitaxel(ABX) intravenous drip

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Glioma1 trial

References

Drug Info

Quick Facts

Related News